Novel immunomic technologies for schistosome vaccine development

Parasite Immunology

Volumn 34, Issue 5, 2012, Pages 276-284

  McWilliam, H E G ^a   Driguez, P ^b   Piedrafita, D ^a   McManus, D P ^b   Meeusen, E N T ^a  

^a MONASH UNIVERSITY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Carbohydrate arrays; Glycobiology; Helminth vaccines; Immunomics; Local antibody; Protein arrays; Schistosomiasis

Indexed keywords

ASPARTIC PROTEINASE; FATTY ACID BINDING PROTEIN; GLUTATHIONE TRANSFERASE; GLYCOSYLPHOSPHATIDYLINOSITOL; PARAMYOSIN; PRAZIQUANTEL; SCHISTOSOMA VACCINE; SERINE PROTEINASE INHIBITOR; TETRASPANIN; TETRASPANIN 2; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANTIBODY TITER; ANTIGENICITY; CARBOHYDRATE ANALYSIS; DICTYOCAULUS VIVIPARUS; DISULFIDE BOND; DRUG SYNTHESIS; ESCHERICHIA COLI; GLYCOBIOLOGY; HAEMONCHUS CONTORTUS; HAEMOPHILUS INFLUENZAE TYPE B; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LARVAL STAGE; LEISHMANIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; ONCHOCERCA VOLVULUS; PARASITOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVIEW; RUMINANT STOMACH; SCHISTOSOMA; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TRICHINELLA SPIRALIS; TRICHOSTRONGYLUS COLUBRIFORMIS; WUCHERERIA BANCROFTI;

ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; DRUG DISCOVERY; HUMANS; SCHISTOSOMA; SCHISTOSOMIASIS; VACCINES;

SCHISTOSOMA; VERMES;

EID: 84859517025     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2011.01330.x     Document Type: Review

References (102)

1. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med 2007; 357: 1018-1027.
2. Steinmann P, Keiser J, Bos R, Tanner M & Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-425.
3. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113: 95-104.
4. Wu HW, Qin YF, Chu K, et al. High prevalence of Schistosoma japonicum infection in water buffaloes in the Philippines assessed by real-time polymerase chain reaction. Am J Trop Med Hyg 2010; 82: 646-652.
5. McManus DP, Gray DJ, Li Y, et al. Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam. Clin Microbiol Rev 2010; 23: 442-466.
6. Guo J, Li Y, Gray D, et al. A drug-based intervention study on the importance of buffaloes for human Schistosoma japonicum infection around Poyang Lake, People's Republic of China. Am J Trop Med Hyg 2006; 74: 335-341.
7. Doenhoff MJ & Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev Anti Infect Ther 2006; 4: 199-210.
8. Gryseels B, Polman K, Clerinx J & Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106-1118.
9. McManus DP & Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21: 225-242.
10. Utzinger J, Bergquist R, Olveda R & Zhou XN. Important helminth infections in Southeast Asia diversity, potential for control and prospects for elimination. Adv Parasitol 2010; 72: 1-30.
11. Capron A, Riveau G, Capron M & Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005; 21: 143-149.
12. Hotez PJ, Bethony JM, Diemert DJ, Pearson M & Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010; 8: 814-826.
13. Bergquist R, Utzinger J & McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2: e244.
14. McManus DP. Prospects for development of a transmission blocking vaccine against Schistosoma japonicum. Parasite Immunol 2005; 27: 297-308.
15. Bickle QD. Radiation-attenuated schistosome vaccination - a brief historical perspective. Parasitology 2009; 136: 1621-1632.
16. Pleasance J, Raadsma HW, Estuningsih SE, Widjajanti S, Meeusen E & Piedrafita D. Innate and adaptive resistance of Indonesian Thin Tail sheep to liver fluke: a comparative analysis of Fasciola gigantica and Fasciola hepatica infection. Vet Parasitol 2011; 178: 3-4.
17. Van Milligen FJ, Cornelissen JBWJ & Bokhout BA. Fasciola hepatica: an antigen fraction derived from newly excysted juveniles, containing an immunoreactive 32-kDA protein, induces strong protective immunity in rats. Exp Parasitol 2000; 94: 163-171.
18. Lightowlers MW. Cestode vaccines: origins, current status and future prospects. Parasitology 2006; 133(Suppl.): S27-S42.
19. Fujiwara RT, Loukas A, Mendez S, et al. Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. Vaccine 2006; 24: 501-509.
20. Bethony J, Loukas A, Smout M, et al. Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB J 2005; 19: 1743-1745.
21. McKeand JB. Vaccine development and diagnostics of Dictyocaulus viviparus. Parasitology 2000; 120: S17-S23.
22. Cho-Ngwa F, Liu J & Lustigman S. The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age. PLoS Negl Trop Dis 2010; 4: e800.
23. Day KP, Gregory WF & Maizels RM. Age-specific acquisition of immunity to infectie larvae in a bancroftian filariasis endemic area of Papua New Guinea. Parasite Immunol 1991; 13: 277-290.
24. Marti HP, Murrell KD & Gamble HR. Trichinella spiralis: immunization of pigs with newborn larval antigens. Exp Parasitol 1987; 63: 68-73.
25. Jacobs HJ, Wiltshire C, Ashman K & Meeusen ENT. Vaccination against the gastrointestinal nematode, Haemonchus contortus, using a purified larval surface antigen. Vaccine 1999; 17: 362-368.
26. Emery DL, McClure SJ, Wagland BM & Jones WO. Studies of stage-specific immunity against Trichostrongylus colubriformis in sheep: immunization by normal and truncated infections. Int J Parasitol 1992; 22: 215-220.
27. Wilson RA & Coulson PS. Schistosome vaccines: a critical appraisal. Mem Inst Oswaldo Cruz 2006; 101(Suppl. 1): 13-20.
28. Wilson RA & Coulson PS. Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite's armour. Trends Parasitol 2009; 25: 423-431.
29. Woolhouse ME & Hagan P. Seeking the ghost of worms past. Nat Med 1999; 5: 1225-1227.
30. Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12: 835-840.
31. Smyth D, McManus DP, Smout MJ, Laha T, Zhang W & Loukas A. Isolation of cDNAs encoding secreted and transmembrane proteins from Schistosoma mansoni by a signal sequence trap method. Infect Immun 2003; 71: 2548-2554.
32. Brito CF, Oliveira GC, Oliveira SC, et al. Sm14 gene expression in different stages of the Schistosoma mansoni life cycle and immunolocalization of the Sm14 protein within the adult worm. Braz J Med Biol Res 2002; 35: 377-381.
33. Moser D, Tendler M, Griffiths G & Klinkert MQ. A 14-kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid binding proteins. J Biol Chem 1991; 266: 8447-8454.
34. Capron A, Riveau GJ, Bartley PB & McManus DP. Prospects for a schistosome vaccine. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2: 281-290.
35. Balloul JM, Pierce RJ, Grzych JM & Capron A. In vitro synthesis of a 28 kilodalton antigen present on the surface of the schistosomulum of Schistosoma mansoni. Mol Biochem Parasitol 1985; 17: 105-114.
36. Balloul JM, Sondermeyer P, Dreyer D, et al. Molecular cloning of a protective antigen of schistosomes. Nature 1987; 326: 149-153.
37. Smith DB, Davern KM, Board PG, Tiu WU, Garcia EG & Mitchell GF. Mr 26, 000 antigen of Schistosoma japonicum recognized by resistant WEHI 129/J mice is a parasite glutathione S-transferase. Proc Natl Acad Sci USA 1986; 83: 8703-8707.
38. Soisson LMA, Masterson CP, Tom TD, McNally MT, Lowell GH & Strand M. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen. J Immunol 1992; 149: 3612-3620.
39. Gobert GN, Stenzel DJ, Jones MK, Allen DE & McManus DP. Schistosoma japonicum: immunolocalization of paramyosin during development. Parasitology 1997; 114 (Pt 1): 45-52.
40. Pearce EJ, James SL & Dalton J. Immunochemical characterization and purification of Sm-97, a Schistosoma mansoni antigen monospecifically recognized by antibodies from mice protectively immunized with a nonliving vaccine. J Immunol 1986; 137: 3593-3600.
41. Lanar DE, Pearce EJ, James SL & Sher A. Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice. Science 1986; 234: 593-596.
42. Harn DA, Mitsuyama M, Huguenel ED & David JR. Schistosoma mansoni: detection by monoclonal antibody of a 22, 000-dalton surface membrane antigen which may be blocked by most molecules on lung stage parasites. J Immunol 1985; 135: 2115-2120.
43. Wright MD, Henkle KJ & Mitchell GF. An immunogenic Mr 23, 000 integral membrane protein of Schistosoma mansoni worms that closely resembles a human tumor-associated antigen. J Immunol 1990; 144: 3195-3200.
44. Harn DA, Mitsuyama M, Huguenel ED, Oligino L & David JR. Identification by monoclonal antibody of a major (28kDa) surface membrane antigen of Schistosoma mansoni. Mol Biochem Parasitol 1985; 16: 345-354.
45. Harn DA, Gu W, Oligino LD, Mitsuyama M, Gebremichael A & Richter D. A protective monoclonal antibody specifically recognizes and alters the catalytic activity of schistosome triose-phosphate isomerase. J Immunol 1992; 148: 562-567.
46. Karcz SR, Barnard BJ & Podesta RB. Biochemical properties of a 24 kilodalton membrane glycoprotein antigen complex from Schistosoma mansoni. Mol Biochem Parasitol 1988; 31: 163-171.
47. Karcz SR, Podesta RB, Siddiqui AA, Dekaban GA, Strejan GH & Clarke MW. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol 1991; 49: 333-336.
48. Cardoso FC, Pacifico RN, Mortara RA & Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol 2006; 144: 382-391.
49. Cardoso FC, Pinho JMR, Azevedo V & Oliveira SC. Identification of a new Schistosoma mansoni membrane-bound protein through bioinformatic analysis. Genet Mol Res 2006; 5: 609-618.
50. Mei H & LoVerde PT. Schistosoma mansoni: the developmental regulation and immunolocalization of antioxidant enzymes. Exp Parasitol 1997; 86: 69-78.
51. Cordeiro da Silva A, LePresle T, Capron A & Pierce RJ. Molecular cloning of a 16-kilodalton Cu/Zn superoxide dismutase from Schistosoma mansoni. Mol Biochem Parasitol 1992; 52: 275-278.
52. Verity CK, McManus DP & Brindley PJ. Developmental expression of cathepsin D aspartic protease in Schistosoma japonicum. Int J Parasitol 1999; 29: 1819-1824.
53. Becker MM, Harrop SA, Dalton JP, Kalinna BH, McManus DP & Brindley PJ. Cloning and characterization of the Schistosoma japonicum aspartic proteinase involved in hemoglobin degradation. J Biol Chem 1995; 270: 24496-24501.
54. Yan Y, Liu S, Song G, Xu Y & Dissous C. Characterization of a novel vaccine candidate and serine proteinase inhibitor from Schistosoma japonicum (Sj serpin). Vet Parasitol 2005; 131: 53-60.
55. Fan J, Gan X, Yang W, Shen L, McManus DP & Brindley PJ. A Schistosoma japonicum very low-density lipoprotein-binding protein. Int J Biochem Cell Biol 2003; 35: 1436-1451.
56. Bergquist NR & Colley DG. Schistosomiasis vaccine: research to development. Parasitol Today 1998; 14: 99-104.
57. Zhou Y, Zheng H, Liu F, et al. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009; 460: 345-351.
58. Liu F, Lu J, Hu W, et al. New perspectives on host-parasite interplay by comparative transcriptomic and proteomic analyses of Schistosoma japonicum. PLoS Pathog 2006; 2: e29.
59. Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S & Wilson A. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics 2006; 6: 1471-1482.
60. Hokke CH, Deelder AM, Hoffmann KF & Wuhrer M. Glycomics-driven discoveries in schistosome research. Exp Parasitol 2007; 117: 275-283.
61. Hokke CH, Fitzpatrick JM & Hoffmann KF. Integrating transcriptome, proteome and glycome analyses of Schistosoma biology. Trends Parasitol 2007; 23: 165-174.
62. Nyame AK, Lewis FA, Doughty BL, Correa-Oliveira R & Cummings RD. Immunity to schistosomiasis: glycans are potential antigenic targets for immune intervention. Exp Parasitol 2003; 104: 1-13.
63. Berriman M, Haas BJ, LoVerde PT, et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009; 460: 352-358.
64. Rinaudo CD, Telford JL, Rappuoli R & Seib KL. Vaccinology in the genome era. J Clin Invest 2009; 119: 2515-2525.
65. Verjovski-Almeida S, DeMarco R, Martins EAL, et al. Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet 2003; 35: 148-157.
66. Pulendran B, Li S & Nakaya HI. Systems vaccinology. Immunity 2010; 33: 516-529.
67. Doolan DL. Plasmodium immunomics. Int J Parasitol 2011; 41: 3-20.
68. Vigil A, Davies DH & Felgner PL. Defining the humoral immune response to infectious agents using high-density protein microarrays. Future Microbiol 2010; 5: 241-251.
69. Meeusen EN & Brandon MR. Antibody secreting cells as specific probes for antigen identification. J Immunol Methods 1994; 172: 71-76.
70. Meeusen E & Brandon M. The use of antibody-secreting cell probes to reveal tissue-restricted immune responses during infection. Eur J Immunol 1994; 24: 469-474.
71. Bowles VM, Brandon MR & Meeusen E. Characterization of local antibody responses to the gastrointestinal parasite Haemonchus contortus. Immunology 1995; 84: 669-674.
72. Tkalcevic J, Brandon MR & Meeusen EN. Fasciola hepatica: rapid switching of stage-specific antigen expression after infection. Parasite Immunol 1996; 18: 139-147.
73. Jungersen G, Eriksen L, Nansen P, Lind P, Rasmussen T & Meeusen EN. Regional immune responses with stage-specific antigen recognition profiles develop in lymph nodes of pigs following Ascaris suum larval migration. Parasite Immunol 2001; 23: 185-194.
74. Balic A, Bowles VM, Liu YS & Meeusen EN. Local immune responses in sensitized sheep following challenge infection with Teladorsagia circumcincta. Parasite Immunol 2003; 25: 375-381.
75. Hoyle DV & Taylor DW. The immune response of regional lymph nodes during the early stages of Fasciola hepatica infection in cattle. Parasite Immunol 2003; 25: 221-229.
76. Walker J, Lee R, Mathy N, Doughty S & Conlon J. Restricted B-cell responses to microbial challenge of the respiratory tract. Vet Immunol Immunopathol 1996; 54: 197-204.
77. Doenhoff MJ. A Vaccine for Schistosomiasis: alternative approaches. Parasitol Today 1998; 14: 105-109.
78. Eberl M, Langermans JAM, Vervenne RA, et al. Antibodies to glycans dominate the host response to schistosome larvae and eggs: is their role protective or subversive? J Infect Dis 2001; 183: 1238-1247.
79. McWilliam HEG, Piedrafita D, Driguez P, McManus DP & Meeusen ENT. The XIIth International Congress of Parasitology, Melbourne, Australia, 2010.
80. Driguez P, Doolan DL, Loukas A, Felgner PL & McManus DP. Schistosomiasis vaccine discovery using immunomics. Parasit Vectors 2010; 3: 4.
81. Driguez P, Ellis M, McWilliam HEG, et al. American Society for Tropical Medicine and Hygiene, 59th Annual Meeting, Atlanta, Georgia, USA, 2010.
82. Cruz-Fisher MI, Cheng C, Sun G, et al. Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice. Infect Immun 2011; 79: 246-257.
83. Doolan DL, Mu Y, Unal B, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008; 8: 4680-4694.
84. Geldhof P, De Maere V, Vercruysse J & Claerebout E. Recombinant expression systems: the obstacle to helminth vaccines? Trends Parasitol 2007; 23: 527-532.
85. Hokke CH & Deelder AM. Schistosome glycoconjugates in host-parasite interplay. Glycoconj J 2001; 18: 573-587.
86. Cummings RD & Nyame AK. Glycobiology of schistosomiasis. FASEB J 1996; 10: 838-848.
87. Astronomo RD & Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 2010; 9: 308-324.
88. Huang YL & Wu CY. Carbohydrate-based vaccines: challenges and opportunities. Expert Rev Vaccines 2010; 9: 1257-1274.
89. Roy R. New trends in carbohydrate-based vaccines. Drug Discov Today 2004; 1: 327-336.
90. Lepenies B & Seeberger PH. The promise of glycomics, glycan arrays and carbohydrate-based vaccines. Immunopharmacol Immunotoxicol 2010; 32: 196-207.
91. Seeberger PH & Werz DB. Synthesis and medical applications of oligosaccharides. Nature 2007; 446: 1046-1051.
92. Nyame AK, Kawar ZS & Cummings RD. Antigenic glycans in parasitic infections: implications for vaccines and diagnostics. Arch Biochem Biophys 2004; 426: 182-200.
93. Harrison GBL, Pulford HD, Doolin EE, Pernthaner A, Shoemaker CB & Hein WR. Antibodies to surface epitopes of the carbohydrate larval antigen CarLA are associated with passive protection in strongylid nematode challenge infections. Parasite Immunol 2008; 30: 577-584.
94. Schofield L, Hewitt MC, Evans K, Siomos MA & Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002; 418: 785-789.
95. Kamena F, Tamborrini M, Liu X, et al. Synthetic GPI array to study antitoxic malaria response. Nat Chem Biol 2008; 4: 238-240.
96. Liu X, Siegrist S, Amacker M, Zurbriggen R, Pluschke G & Seeberger PH. Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem Biol 2006; 1: 161-164.
97. Kariuki TM, Farah IO, Wilson RA & Coulson PS. Antibodies elicited by the secretions from schistosome cercariae and eggs are predominantly against glycan epitopes. Parasite Immunol 2008; 30: 554-562.
98. Vervelde L, Bakker N, Kooyman FNJ, et al. Vaccination-induced protection of lambs against the parasitic nematode Haemonchus contortus correlates with high IgG antibody responses to the LDNF glycan antigen. Glycobiology 2003; 13: 795-804.
99. Geldhof P, Newlands GFJ, Nyame K, Cummings R, Smith WD & Knox DP. Presence of the LDNF glycan on the host-protective H-gal-GP fraction from Haemonchus contortus. Parasite Immunol 2005; 27: 55-60.
100. Wuhrer M, Dennis RD, Doenhoff MJ, Lochnit G & Geyer R. Schistosoma mansoni cercarial glycolipids are dominated by Lewis X and pseudo-Lewis Y structures. Glycobiology 2000; 10: 89-101.
101. Blixt O, Head S, Mondala T, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA 2004; 101: 17033-17038.
102. van Stijn CM, van den Broek M, Vervelde L, et al. Vaccination-induced IgG response to Galalpha1-3GalNAc glycan epitopes in lambs protected against Haemonchus contortus challenge infection. Int J Parasitol 2010; 40: 215-222.